Navigation Links
Anesiva Announces Hiring of Sales Force for FDA-Approved Product Zingo(TM)
Date:1/30/2008

ultiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward- looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, whether Anesiva is able to manufacture its products on commercially reasonable terms, whether Anesiva can secure FDA approval for the use of Zingo in adults, and the degree to which Zingo gains market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's quarterly report on Form 10-Q for the quarter ended September 30, 2007.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue relia
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Anesiva to Unveil Zingo(TM) Commercialization Plans
2. Anesiva to Present at BIO InvestorForum on October 11, 2007
3. Anesiva to Announce Third Quarter 2007 Financial Results and Host Webcast Conference Call on November 1, 2007
4. Anesiva Announces Upcoming Webcasts and Conference Participation
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 2015 On November 24, 2014, Per Wickstrom ... to discuss the problem of substance abuse and the solutions ... of drug abuse and recovery, gives a unique first-person perspective ... his teammates on the New York Giants, Taylor’s early career ... drug tests, yet he was able to straighten out long ...
(Date:3/31/2015)... Angeles, CA (PRWEB) March 31, 2015 ... references on the Internet, is proudly enduring adding news ... cosmetic doctors and the consumers of plastic surgery and ... With more user-friendly pages and interconnected sections, the Cosmetic ... The newest addition to the Cosmetic Town site navigation, ...
(Date:3/31/2015)... The American College of Traditional Chinese ... April will include interesting workshops, lectures and more. The ... a.m. April 6, ACTCM welcomes the newest cohort. The ... Pioneer Square Campus located at 555 DeHaro St. , ... 14, Students will be updated on the upcoming merger ...
(Date:3/31/2015)... Stamford, CT (PRWEB) March 31, 2015 Calling ... fight against Lyme and other tick-borne diseases! The first annual ... at Cove Island Park in Stamford, CT. The event, hosted ... Alliance (TBDA), will raise funds to support research and ... family event, open to all ages and abilities, will feature ...
(Date:3/31/2015)... Medical DNA Labs, LLC, An Affiliate of Physician ... Accreditation by COLA, a national healthcare accreditation organization. ... standards of quality in day-to-day operations, demonstrate continued accuracy ... rigorous on-site laboratory survey. Medical DNA Labs, LLC ... long-term commitment to provide quality service to its patients. ...
Breaking Medicine News(10 mins):Health News:Lawrence Taylor & Per Wickstrom Discuss the Drug Rehabilitation & Recovery Process 2Health News:Cosmetic Town is Now Transforming so Consumer can Better Navigate 2Health News:ACTCM Announces April Event Schedule 2Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2Health News:Local Medical DNA Labs, LLC. Recognized for Quality Laboratory Services 2
... June 29 Air Methods Corporation (Nasdaq: AIRM ... announced today it has filed a petition with the National ... cause determination related to the June 29, 2008 mid-air collision ... states that "both pilots failed to see and avoid the ...
... Helicobacter pylori survives in the body by manipulating ... thesis from the Sahlgrenska Academy at the University of ... against the common peptic ulcer bacterium. About half ... mainly in the stomach. Most infected individuals never experience ...
... Black gay men have less choice when it comes to sexual ... are closely knit. These tightly interconnected networks make the rapid spread ... social and sexual mixing between ethnic groups in men who have ... San Francisco Department of Public Health in the US, show that ...
... new study by The Pew Charitable Trusts, Philadelphia Research Initiative reports ... money it needs to make good on its obligation to past ... underfunded since 1996, and there is little prospect that the picture ... The report, Quiet No More: Philadelphia Confronts the ...
... AMSTERDAM, June 29 , ... Hiring and,Collaboration Decisions , Elsevier, ... and services, today announced the launch of SciVal,Spotlight, a ... of research performance to evaluate, establish,and execute more informed ...
... new type of body armour made from cement. The new ... make a material tough enough to withstand most types of bullets. ... is being carried out the School of Civil Engineering at the ... said: "By using cement instead of alumina we are confident we ...
Cached Medicine News:Health News:Air Methods Petitions NTSB for Reconsideration of Probable Cause Determination 2Health News:Black gay men may be at increased HIV risk 2Health News:Pew Report Documents Challenges Faced by Philadelphia in Paying for City Workers' Pensions and Health Care 2Health News:Pew Report Documents Challenges Faced by Philadelphia in Paying for City Workers' Pensions and Health Care 3Health News:Pew Report Documents Challenges Faced by Philadelphia in Paying for City Workers' Pensions and Health Care 4Health News:Pew Report Documents Challenges Faced by Philadelphia in Paying for City Workers' Pensions and Health Care 5Health News:Pew Report Documents Challenges Faced by Philadelphia in Paying for City Workers' Pensions and Health Care 6Health News:Elsevier Launches SciVal Spotlight: New Tool Provides Multidisciplinary View of Research Performance 2Health News:Elsevier Launches SciVal Spotlight: New Tool Provides Multidisciplinary View of Research Performance 3Health News:Elsevier Launches SciVal Spotlight: New Tool Provides Multidisciplinary View of Research Performance 4
(Date:3/31/2015)... Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: ... expand its planned bullous pemphigoid (BP) clinical development for ... Pemphigoid is an orphan auto-immune blistering disease of the ... Europe . As previously ... Phase II clinical trial in Israel ...
(Date:3/31/2015)... 2015 ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... 150mg, 225mg and 300mg oral tablets, indicated for use ... market for Propafenone Hydrochloride 150mg, 225mg and 300mg tablets ... Arthur S. Przybyl , President and Chief ... launch of our fourth product from the portfolio of ...
(Date:3/31/2015)... 2015   Unique Pharmaceuticals , a 503B outsourcing ... the company has initiated sterile compounding operations meeting the ... a company is to meet and exceed industry standards," ... the new regulations is validation of our quality management ... of our industry, investing in its continued success and ...
Breaking Medicine Technology:Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 2Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 4ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 2Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 3
... Delivery System Has Potential to, Help Solve Radiation Therapy Access and ... ... Symposium, WASHINGTON, Sept. 8 Early clinical experience with the,FDA ... non-isotopic treatment is a viable,option for adjuvant therapy for early-stage breast ...
... Compared to FISH ... - Company to Include Reporting for HER2 Gene Expression in All Oncotype DX ... Reports by End ... GHDX ) today announced results from two studies demonstrating,that quantitative reporting for ...
Cached Medicine Technology:Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium 2Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium 3Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5
Inquire...
... Eliminate aerosol contamination, ... reactions in PCR. Hydrophobic, ... Only air can pass ... tips, in contrast to ...
300 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 250 and 300 L pipettes....
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Medicine Products: